Vitrafy Life Sciences Ltd. · ASX:VFY
Vitrafy Life Sciences — Investor Presentation (June 2026)
27 slides from Vitrafy Life Sciences's investor presentation, Jun 3, 2026
Slide 1: Vitrafy Life Sciences: Pioneering Technology, Preserving Life
For personal use only Vitrafy Life Sciences Pioneering Technology, Preserving Life. Building the foundational infrastructure for the global biologics economy. One cryopreservation platform. Animal reproduction, blood, cell & gene therapy — and beyond. ASX: VFY | June 2026 | vitrafy.com | Strictly Pr
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer For personal use only This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). invitation or recommendation to purchase any securities in the United States and neither this Statements in this presentation are made only as at the
Slide 3: Important Notice and Disclaimer
Important Notice and Disclaimer For personal use only Not financial product advice Financial data Reliance should not be placed on the information or opinions contained in this presentation. All figures in the presentation are Australian dollars ($ or A$) unless stated otherwise. A number of This pr
Slide 4: Company Highlights
Company Highlights Foundational infrastructure for the biologic's economy — validated science, commercial traction, and upcoming value catalysts. For personal use only Cryopreservation-as-an- Step-Change in Scientific Critical Market Need Ecosystem Outcomes • Cryopreservation solution covering the e
Slide 5: The U.S. Blood Industry Faces a 2027 Infrastructure Replacement Cycle
The U.S. Blood Industry Faces a 2027 Infrastructure Replacement Cycle For personal use only Two structural failures converging in the US blood market alone — creating an inflection point now. PROBLEM 1 PROBLEM 2 Chronic Shortages End-of-Life Technology • Blood platelets last less than 7 days at room
Slide 6: The Ecosystem
For personal use only The Ecosystem Wholistic cryopreservation solution delivering quality at every-step. 6
Slide 7: What is Cryopreservation?
What is Cryopreservation? The science & engineering of preserving biological materials at low temperatures that For personal use only underpins many areas of the healthcare system. BUILT IN THE ‘60’s, STUCK IN THE ‘60’s Commercial Workflow Sample & Applications Issues Quality Issues • Blood products
Slide 8: Cryopreservation-as-an-Ecosystem
Cryopreservation-as-an-Ecosystem One integrated platform — hardware, software, and consumables — that embeds, then expands – continuous improvement For personal use only and value creation. QUALITY DRIVER DATA MOAT ECOSYSTEM CONNECTION REVENUE DRIVER FREEZING DEVICE CLOUD SOFTWARE POINT-OF-CARE RECU
Slide 9: Differentiated Technology Solution
Differentiated Technology Solution Vitrafy’s IP protected technology solution has a clear competitive advantage that may unlock entirely new market For personal use only opportunities. QUALITY BROAD USE SPEED VALUE • Superior post thaw quality • One solution – multiple outcomes - consistently. uses.
Slide 10: The Science
For personal use only The Science A step-change in scientific outcomes, consistently. 10
Slide 11: Validated Science – Blood Platelets
Validated Science – Blood Platelets For personal use only First-to-Market Opportunity No FDA-approved cryopreserved platelet product currently exists 100.0% 94.4% in the US. 90.0% 80.0% Exceeds Benchmarks USA fresh guideline (75%) 94.4% recovery exceeds European regulatory standard and 70.0% FDA/AAB
Slide 12: Validated Science – T-Cell (CGT)
Validated Science – T-Cell (CGT) For personal use only Growing Market Vitrafy post thaw T-Cell Viability Over 900 cell and gene therapy clinical trails (USA), requiring 100% 95% 94% quality cryopreserved materials. Transformative new pillar of 93% 93% medicine, engineering cells to fight disease. 90
Slide 13: Validated Science – Animal
Validated Science – Animal For personal use only Salmon Fertilisation Rate Commercial Technology Validation 80% Year-on-year business model and ecosystem strategy success in 75% 72% unregulated markets. 70% 60% Commercialised Product Offering Vitrafy has commercialised its cryopreservation-as-an-eco
Slide 14: Commercial Traction
For personal use only Commercial Traction One solution, multiple go-to-market applications. 14
Slide 15: Priority Verticals Strategies and Catalysts
Priority Verticals Strategies and Catalysts One solution, multiple go-to-market applications. Vitrafy has prioritised three areas. For personal use only Animal Reproduction Blood Cell & Gene Therapy ▪ Food security and production ▪ Technology obsolescence ▪ Requires standardisation Growth ▪ Increase
Slide 16: Critical Market
For personal use only Critical Market Two critical structural problems, demanding immediate market change. U.S. Blood Market Snapshot: 14.2m blood collections annually ~6,100 hospitals across the U.S. ~1,000+ fixed site donation centers 16
Slide 17: No one should die from a lack of supply of life-saving blood
No one should die from a lack of supply of life-saving blood For personal use only CRITICAL SUPPLY DONATION SHORTAGES FAILURES DECLINE 17
Slide 18: Blood Products
Blood Products For personal use only A deliberate and targeted market entry strategy across military & civilian use. Military Scientific Civilian Multiple Product Validation Expansion Applications In Vitro Phase I/II complete Identified urgent market need – Land & expand strategy 94% post thaw quali
Slide 19: Vitalant: First Major U.S. Blood Network Deployment
Vitalant: First Major U.S. Blood Network Deployment For personal use only Vitrafy has partnered with one of the largest blood networks in America Vitalant — Land & Expand Potential launch partner for next-generation red blood cell cryopreservation solutions. Aim to rapidly address the global critica
Slide 20: Blood: The U.S. blood collection network
Blood: The U.S. blood collection network Concentrated blood supply networks with a small number networks representing a material market opportunity. For personal use only The U.S. Blood Collection Network* Blood Network Concentration 1200 Over 1,000 fixed collection sites across the U.S. Below are e
Slide 21: Animal Reproduction
For personal use only Animal Reproduction Cryo-enabled animal reproduction for global food supply— led by bovine and aquaculture. Animal Reproduction Snapshot: US$6B global animal artificial insemination 2,200 collection sites. market – led by bovine at ~50% of market 21
Slide 22: Animal Reproduction: IMV Technologies Partnership
Animal Reproduction Signed commercial agreement with IMV technologies to prepare for a joint go-to-market global offering. For personal use only IMV Technologies — Global Partner Global partnership secured with IMV Technologies to develop a Global go-to- market offering. Revenue generating - ~$0.9m
Slide 23: Business Model
For personal use only Business Model Translating a scientific step-change into a high-margin, recurring business model. 23
Slide 24: Recurring Revenue Model
Recurring Revenue Model Recurring managed-service economics that compound with every installed device. For personal use only Installed Device Count > Recurring Monthly Service Fee + Consumable fee 01 02 03 Managed Service Smart Consumables Compounding Moat HARDWARE + SOFTWARE + SERVICE PER-CYCLE REV
Slide 25: Outlook
For personal use only Outlook Multiple, upcoming value inflection points approaching. 25
Slide 26: Value Creation Roadmap
Value Creation Roadmap Milestone-driven value creation across FY26–FY27 with near-term catalysts in both regulated and unregulated markets. For personal use only ✓ COMPLETE CLEAR UPCOMING VALUE CREATION ACTIVITIES Ecosystem Validated FDA Approvals – Land & Expand – Broadscale Adoption Q4 FY26 — Prod
Slide 27: The Window Is Now: Cryopreservation is broken. Vitrafy is the fix.
ASX: VFY | THE WINDOW IS NOW For personal use only Cryopreservation is broken. Vitrafy is the fix. Validated Clear Market Commercial Deliver Value Technology need Ready 94.4% Post-thaw recovery Forcing event — Revenue generating today Customer & Patient outcomes best in class no approved alternative
Vitrafy Life Sciences — Investor Presentation (June 2026) on 6ix